The collaboration between Nutriband Inc. (NASDAQ: NTRB) and Kindeva has reached a pivotal milestone with the successful scale-up of the commercial manufacturing process for Aversa Fentanyl. This development is not just a technical achievement but a beacon of hope in the ongoing battle against opioid abuse. Aversa Fentanyl, which combines Nutriband’s AVERSA abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch, is poised to become the world’s first abuse-deterrent opioid patch. The significance of this advancement cannot be overstated, as it represents a potential turning point in how opioids are prescribed and used, with the aim of significantly reducing the risks of abuse, misuse, and accidental exposure.
The implications of this development are vast. With the opioid crisis continuing to devastate communities worldwide, the introduction of an abuse-deterrent opioid patch could play a critical role in curbing the epidemic. Nutriband projects that Aversa Fentanyl could achieve peak U.S. sales between $80 million and $200 million, underscoring the market’s readiness for innovative solutions to opioid abuse. Furthermore, the product’s extensive international patent portfolio hints at its potential global impact, offering a glimpse into a future where opioid abuse could be significantly mitigated through technological advancements.
The next steps for Nutriband and Kindeva involve producing clinical supplies and submitting an Investigational New Drug application to initiate a human abuse liability study. These steps are crucial in ensuring the safety and efficacy of Aversa Fentanyl, bringing it one step closer to market availability. The collaboration between Nutriband and Kindeva exemplifies how partnerships between innovators and manufacturers can accelerate the development of solutions to some of the world’s most pressing health challenges. As the project moves forward, the healthcare industry and patients alike will be watching closely, hopeful for a new tool in the fight against opioid abuse.
This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Nutriband Inc. and Kindeva Scale Up Commercial Manufacturing of Aversa Fentanyl, Pioneering Abuse-Deterrent Opioid Patch.
